Featured Story EyeCool Therapeutics Announces Promising Results from Double-Masked Randomized Controlled Trial in Chronic Ocular Surface Pain (COSP) May 7, 2025-EyeCool Therapeutics
Sera Prognostics Added to Russell 2000 and 3000 Indexes Following Conclusion of 2024 Indexes Annual Reconstitution July 1, 2024-Sera Prognostics
Epitel Announces Appointment of Wearables Industry Leader Ken Nelson to Board of Directors June 26, 2024-Epitel
Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain May 14, 2024-Brixton Biosciences
Epitel Receives FDA 510(k) Clearance for Two New Technologies: REMI Remote EEG Monitoring System for Ambulatory Use and REMI Vigilenz AI For Event Detection April 23, 2024-Epitel
Avive Solutions Raises $56.5M in Growth Funding To Build Connected AED Network and Transform Cardiac Arrest Emergency Response in Communities Nationwide April 18, 2024-Avive
Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System February 27, 2024-Aria CV
Sera Prognostics Announces Primary Endpoint Criteria Met in Pivotal Prime Study Interim Look – Enrollment to Stop Due to Success December 6, 2023-Sera Prognostics
BRIXTON BIOSCIENCES’ COOLIO™ THERAPY GRANTED BREAKTHOUGH DEVICE DESIGNATION BY FDA October 26, 2023-Brixton Biosciences
